Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial-Reference-Cited by-同舟云学术

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Published:2023-07 Issue:7 Volume:22 Page:568-577
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Corboy John R,Fox Robert J,Kister Ilya,Cutter Gary R,Morgan Charity J,Seale Rebecca,Engebretson Eric,Gustafson Tarah,Miller Aaron E,Bourdette Dennis,Yadav Vijayshree,Goodman Andrew,Racke Michael,Fallis Robert,Tornatore Carlo,Goldman Myla,Kannan Meena,Sriram Subramaniam,Berger Joseph,Cross Anne,Rammohan Kottil,Xia Zongqi,Leist Thomas,Lynch Sharon,Klawiter Eric,Amezcua Lilyana,Bowen James

Funder

National Multiple Sclerosis Society

Patient-Centered Outcomes Research Institute

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference30 articles.

1. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology;Rae-Grant;Neurology,2018

2. Diagnosis and treatment of multiple sclerosis: a review;McGinley;JAMA,2021

3. The prevalence of MS in the United States: a population-based estimate using health claims data;Wallin;Neurology,2019

4. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis;Schweitzer;Curr Opin Neurol,2019

5. Natural history of multiple sclerosis: a unifying concept;Confavreux;Brain,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations;Multiple Sclerosis Journal;2024-09-08

2. Understanding the Complex Dynamics of Immunosenescence in Multiple Sclerosis: From Pathogenesis to Treatment;Biomedicines;2024-08-19

3. Data-driven risk/benefit estimator for multiple sclerosis therapies;2024-08-17

4. MS treatment de-escalation: review and commentary;Journal of Neurology;2024-08-02

5. Real-world effectiveness of disease-modifying therapies in older adults with multiple sclerosis;Journal of Medicine, Surgery, and Public Health;2024-08